Predictive Vulnerability Intelligence.

Product

  • Product
  • Pricing
  • Documentation

Company

  • About
  • Partnerships
  • Blog
  • Support

Legal

  • Terms
  • Privacy
  • Data Licensing

© 2026 FAUCET Technologies LLC. All rights reserved.

Dexma

First CVE: Oct 19, 2023Active for: 3 yearsTotal CVEs: 5

Dexma's vulnerability footprint centers on its DexGate energy-management and building-automation product, with a durable signal in web application and credential-handling weaknesses including cleartext transmission of sensitive data, cross-site scripting, cross-site request forgery, and improper authentication. Live severity, exploitation, and exposure counts are shown alongside this summary.

FAUCET AI Generated
5
Total CVEs
More Total CVEs than 83% of tracked vendors
5.0
Avg CVEs / Product / Year
More Avg CVEs / Product / Year than 97% of tracked vendors
7.1
Avg CVSS Score
Higher Avg CVSS Score than 51% of tracked vendors
0.0%
In CISA KEV
Bottom 1%

Trends Over Time

The number and severity of CVEs published that impact products developed by Dexma over time

Volume of CVEsAvg CVSS Base Score
First CVE
Oct 19, 2023
2 years ago
Most Recent CVE
Oct 19, 2023
1,010 days ago

Products(1 total)

Top CVEs

Signals from CVEs in this vendor scope (5 CVEs).

5 CVEs · Highest risk first

CVEPublishedCVSSRiskKEVExploit
CVE-2023-42435HIGH
The affected product is vulnerable to a cross-site request forgery vulnerability, which may allow an attacker to perform actions with the permissions of a victim user.
Oct 19, 20238.826NONO
CVE-2023-41089HIGH
The affected product is vulnerable to an improper authentication vulnerability, which may allow an attacker to impersonate a legitimate user as long as the device keeps th
Oct 19, 20238.824NONO
CVE-2023-41088MEDIUM
The affected product is vulnerable to a cleartext transmission of sensitive information vulnerability, which may allow an attacker with access to the network, where clie
Oct 19, 20236.519NONO
CVE-2023-40153MEDIUM
The affected product is vulnerable to a cross-site scripting vulnerability, which could allow an attacker to access the web application to introduce arbitrary Java Script by injec
Oct 19, 20236.119NONO
CVE-2023-42666MEDIUM
The affected product is vulnerable to an exposure of sensitive information to an unauthorized actor vulnerability, which may allow an attacker to create malicious requ
Oct 19, 20235.317NONO
View all 5 CVEs →

CVE Severity & Scoring

Severity distribution of CVEs that affect this vendor's products5 CVEs
60%
40%
Severity distribution among all CVEs352,708 CVEs
45%
40%
11%
MediumHigh
Attack Vector
Local0 (0.0%)
Network5 (100.0%)
Unknown0 (0.0%)
Physical0 (0.0%)
Adjacent Network0 (0.0%)
Attack Complexity
Low5 (100.0%)
High0 (0.0%)
Unknown0 (0.0%)
User Interaction
None1 (20.0%)
Unknown0 (0.0%)
Required4 (80.0%)
Privileges Required
Low0 (0.0%)
High0 (0.0%)
None5 (100.0%)
Unknown0 (0.0%)

Exploit Exposure

Signals from CVEs in this vendor scope (5 CVEs).

CISA KEV
0 CVEs
0.0% of CVEs· Bottom 1%
Metasploit
0 CVEs
0.0% of CVEs· Bottom 1%
Nuclei
0 CVEs
0.0% of CVEs· Bottom 1%
ExploitDB
0 CVEs
0.0% of CVEs· Bottom 1%

Social Chatter

An overview of all social media posts that mention a CVE ID that affects a product developed by Dexma.

Media Mentions

Media articles that mention a CVE ID that affects a product developed by Dexma — matched by CVE ID, not by vendor name.

Top CNAs Publishing CVEs For Dexma's Products

View all 1 CNAs →

Top CWEs